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Abstract 
Risk adjustment and payment systems rely on an accurate understanding of the 
drivers of healthcare costs. A related concern is whether certain cases of 
multimorbidity coincide with notably higher costs of healthcare. With the 
utilisation of administrative data for over 250,000 Australian residents, we 
investigate whether there are specific combinations of morbidities that are 
associated with amplified healthcare costs. Chi-square automated interaction 
detection is used to identify the key interactions of morbidities that drive 
healthcare cost across four healthcare sector categories (i.e. medical services, 
pharmaceutical, hospital and total healthcare). Using simultaneous quantile 
regressions, the performance of models that include morbidity interaction 
variables is assessed at multiple points of the distribution (i.e. the 10th, 50th, 
90th, 95th and 98th percentiles). Key drivers of risk included in these models 
include age, body mass index (BMI), individual morbidity groups and imminent 
death. Our work builds on previous studies that have tended to focus on 
aggregate expenditure or primary healthcare costs but have not assessed how 
model performance differs across the distribution of costs. For all four 
categories of healthcare costs we find that a morbidity dummy and interaction 
variable model performs notably better than a model that uses a count variable 
of the number of coexisting morbidities. This is especially the case for the right 
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1 Introduction 
Redesigning healthcare interventions to better manage cases where more than one morbidity prevails 
has been identified as a key challenge for healthcare systems and, accordingly, this has fuelled interest 
in coordinated and integrated care programs (Guthrie et al. 2008, Barnett et al. 2012, Haggerty 2012, 
Smith et al. 2012, Tinetti, Fried, and Boyd 2012). The focus on comorbidity (i.e. two morbidities) and 
multimorbidity (i.e. three or more morbidities) has been, in part, motivated by the success of treating 
mid-life health conditions and concerns about the adequacy of healthcare systems that have been 
largely configured to treat individual diseases (Barnett et al. 2012, Salisbury 2012, Banerjee 2015). 
While there has been a broad discussion of multimorbidity and the consequences this has on 
managing the healthcare system, the literature that focuses on estimating the cost of healthcare has 
tended to treat morbidity as individual diseases and it is rare for these models to account for cost 
amplifications associated with morbidity interactions. In this paper, our aim is to identify morbidity 
interactions that are related to the cost of healthcare and confirm whether the inclusion of these 
interactions improves the performance of models of healthcare costs. Using simultaneous quantile 
regression, we perform this assessment for multiple points of four cost distributions with an allowance 
for key drivers of risk, specifically age, body mass index (BMI), individual morbidity groups and 
imminent death. 
 
Refinements in the modelling of healthcare costs have widespread applications and will assist in 
making accurate adjustments for risk that are relevant to the development and revision of payments 
systems (including primary care capitation payments, hospital reimbursement based on case-mix 
weighted payments and the risk-equalisation of insurance premiums). Our focus on the importance of 
morbidity interaction variables is also motivated by previous studies that include morbidities within 
models of healthcare cost in an individual manner (Ellis et al. 2013, Buchmueller and Johar 2015, 
Jones, Lomas, and Rice 2015, Jones et al. 2016); studies that found that models with a count variable 
of coexisting morbidities performed better than models with complex multimorbidity measures 
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variables with limited improvement in the performance of risk adjustment models (Buchner, Wasem, 
and Schillo 2017, van Veen et al. 2017). It should be noted that a count variable of the number of 
coexisting morbidities and morbidity interaction variables are distinct and capture different 
relationships. A key distinction is the equal weighting of all morbidities when using a count variable, 
as opposed to, making an allowance for certain combinations of morbidities that have a simultaneous 
influence that is not additive (i.e. interaction variable).   
 
The importance of morbidity interactions remains ambiguous. For example, Buchner, Wasem, and 
Schillo (2017) used a large dataset of nearly 2.9 million individuals residing in Germany to identify 
morbidity interactions using a regression tree analysis; and while they found a marginal improvement 
in models of risk adjustment, they concluded that the current approach of disregarding interactions 
was not problematic. In contrast, there are a range of studies that have found that multimorbidity is 
related to the cost of healthcare (Schoenberg et al. 2007, Lehnert et al. 2011, König et al. 2013, 
Sambamoorthi, Tan, and Deb 2015, van Veen et al. 2017). It is important to note that van Veen et al. 
(2017) used a similar methodology and found similar results to those in Buchner, Wasem, and Schillo 
(2017); however, they concluded that interaction terms can improve the prediction of healthcare costs 
for both the overall population and specific subgroups in the population.  
 
The focus of this analysis is to investigate the importance of interactions between morbidities for 
accurately modelling aggregate healthcare costs, as well as, costs in three different healthcare sectors. 
The use of administrative data for over 250,000 Australian residents allows us to focus on the costs 
associated with multiple categories of healthcare sectors; specifically, medical services, 
pharmaceuticals, admitted patient care as well as the aggregate of these costs. At issue is the discrete 
treatment of morbidities and the use of count variables that do not account for the complexity that 
comorbidity and multimorbidity presents to the healthcare system. We expect that these complexities 
lead to increased costs of healthcare. Substantial increases in costs may be driven by a range of 
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extended lengths of stay or the coincidence of a combination of conditions that make treatment more 
complex, intensive or risky. Identifying costly morbidity interactions has the potential to inform the 
development or prioritisation of policies that aim to prevent the escalation of costs associated with 
multimorbidity. In relation to multimorbidity, it has been noted that the system of specialist referrals 
is inefficient and ineffective (Wolff, Starfield, and Anderson 2002, Starfield, Shi, and Macinko 2005, 
Burgers et al. 2010). It has also been found that clinical and prescribing guidelines tend to provide 
limited advice to clinicians on how they should prioritise recommendations across multiple distinct 
diseases (Boyd et al. 2005, van Weel and Schellevis 2006, Van Spall et al. 2007). In accordance with 
this, it was noted in Barnett et al. (2012) that patients with multimorbidity may be prescribed several 
drugs that are recommended by individual disease-specific guidelines, but the simultaneity of certain 
conditions may result in the overall drug burden being difficult for patients to manage and potentially 
harmful (Barnett et al. 2012).  
 
Previous studies have not examined the importance of multimorbidity in a model of healthcare costs 
at different points of the distribution. Our analysis will address this gap in the literature by using 
simultaneous quantile regression to examine model performance across multiple points of four cost 
distributions. This technique is employed to estimate the effects of morbidity, comorbidity and 
multimorbidity variables for patients who incur low (i.e. the 10th percentile), median (50th 
percentile), high (i.e. the 90th percentile) and extremely high (i.e. the 95th and 98th percentiles) 
healthcare costs. It should be noted that the focus on performance at different points of the distribution 
is, in part, motivated by the findings of Eckardt et al. (2016) as they found ‘two diametrically opposed 
cost trends’ that were related to the number of co-occurring diseases. It is also motivated by the work 
of de Meijer et al. (2013) and Jones, Lomas, and Rice (2015) who recommend further research on 
healthcare costs that explore the full distribution of healthcare costs and goes beyond a focus on 
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We make a distinction between cases where patients have two morbidities (i.e. comorbidity) and three 
or more morbidities (i.e. multimorbidity) to distinguish between the complexity of the interactions in 
terms of the number of coexisting morbidities. It should be noted that there are different definitions of 
multimorbidity that are commonly used within the literature (Diederichs, Berger, and Bartels 2011, 
van den Akker et al. 2001, Le Reste et al. 2013, Harrison et al. 2014). Some studies specify that the 
medical conditions should be limited to chronic diseases, however, we follow the definition 
prescribed by van den Akker, Buntinx, and Knottnerus (1996), which includes chronic diseases, acute 
diseases and other medical conditions.  
 
In this paper, we will use a statistical interaction detection approach to identify morbidity interaction 
variables that are related to high/low healthcare costs. With the use of Chi-square automated 
interaction detection (CHAID), we are able to exhaust a very large number of possible interactions to 
identify the morbidity interaction groups that are associated with each category of healthcare cost. The 
possible number of interaction variables that can built using 60 morbidity dummy variables (with 0 
and 1 as unique classifications) and a large order of interactions is extremely large. Identifying the 
relevant interactions for four categories of healthcare without an automated technique is unlikely to 
result in an exhaustive range of interaction variables. Our argument in favour of using interaction 
detection in this manner is similar to that used by Belloni et al. (2014) when discussing variable and 
functional form selection with high dimensional data. Note that high dimensional data are data that 
have a large number of variables relative to the sample size (Belloni, Chernozhukov, and Hansen 
2014a). Note that Einav and Levin (2014), Varian (2014) and Athey (2017) have also advocated for 
the use of automated data driven techniques within empirical economics. The use of the CHAID 
approach has been chosen as it is specifically designed for categorical variables, produces complex 
tree structures (as it allows for more than two splits) and reduces the likelihood of over-fitting (i.e. 
being biased towards selecting predictors with more categories) by filtering out variables that are not 
related to the dependent variable using a statistical association test (van Diepen and Franses 2006, 
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relation to deciles of a specific category of healthcare cost. Previous studies have been critiqued for 
using multimorbidity measures that were not designed with costs in mind (Lapi et al. 2015). 
2 Methodology 
Our methodology is described in three parts. The first section outlines the model of healthcare costs 
and specifies the procedure used to estimate costs for multiple points of the distribution. The second 
section outlines the interaction detection technique used to identify potentially important interaction 
variables. This includes a discussion of the need to distinguish between data mining as a ‘fishing’ 
exercise and as a variable specification tool applied to a well-defined set of variables. The third 
section outlines our use of the coefficient of determination to assess improvements in model 
performance within specific sub-samples based on the number of morbidities and whether the 
individual dies in the year of interest or the next year. 
2.1 Specification of a model of annual healthcare cost 
The first model of cost (Model 1 – M1) is specified in a similar manner to that in Brilleman et al. 
(2014) with differences in morbidity profiles captured using a count variable of the number of 
coexisting morbidities. The second model (Model 2 – M2) is built using a model specification similar 
to that used by Ellis et al. (2013), Brilleman et al. (2014) and Jones, Lomas, and Rice (2015) with 
morbidity included as distinct dummy variables. The third model (Model 3 – M3) that we estimate is 
expected to improve upon model two by including morbidity interaction variables. Equation one 
defines the model that determines the level of annual non-zero healthcare costs. Specified as 
subscripts are the four types of healthcare, h, that we focus on with costs, C, specified as an annual 
cost for each individual, i. The cost categories, h, are medical services, pharmaceuticals, admitted 
patient care and the aggregate of these costs.  is a vector of patient characteristics that are expected 
to influence the annual cost of each type of healthcare. For each type of healthcare  are the vectors 
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          (1) 
 
We estimate the effects of the explanatory variables for different points of the conditional distribution 
using simultaneous quantile regression. The quantile regression model that we estimate for the τth 
percentile of each type of healthcare cost is given by 
 
           (2) 
 
 
where τ=0.1, 0.5, 0.9, 0.95, 0.98. This coincides with estimates for the 10th, 50th, 90th, 95th and 98th 
percentiles and allows us to confirm whether improvements in model performance are associated with 
low, median, high and extremely high healthcare costs. The equations for these five percentiles are 
estimated simultaneously using the sqreg command in Stata and the variance–covariance matrix of the 
estimators is obtained using bootstrapping. 
 
Corresponding to the specification in the aforementioned papers, the variables included in the  
vector of explanatory variables includes morbidity, demographic, economic, lifestyle and health status 
dummy variables. Note that Table 1A in the appendix contains the specification of the explanatory 
variables included in the three models of healthcare cost. In addition to the variables used in previous 
papers, we also include dummy variables that capture whether a patient dies during the year of 
observation or the next. This is motivated by research that has found that time to death is a notable 
driver of healthcare costs (Zweifel, Felder, and Meiers 1999, Werblow, Felder, and Zweifel 2007, 
Felder, Werblow, and Zweifel 2010). An additional difference to past studies of healthcare costs is the 
use of a morbidity index that simultaneously uses hospital diagnoses and ambulatory drugs 
dispensation to specify the morbidity grouping. The Diagnosis and Drug Morbidity Grouping 
(DDMG), which was developed by Halfon et al. (2013), is used as morbidities can be specified for all 
patients and cost distributions no matter whether a hospitalisation occurred or not. The DDMG 
specifies sixty morbidity classifications using the International Classification of Diseases (ICD) codes 
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variables for morbidities that are included in models two and three. Within the third model we include 
dummy variables of morbidity interactions that capture comorbidity and multimorbidity health states. 
The first model is distinct as it does not have sixty morbidity dummy variables, but contains a count 
variable of the number of coexisting morbidities that is also constructed using the DDMG.  
2.2 Identifying morbidity interactions  
To identify the combinations of interactions to include in the multimorbidity healthcare cost model we 
decided that a statistical interaction detection technique would be most suitable. This was based on 
having an extremely large number of possible interactions between 60 morbidity variables and a 
limited number of studies that assess the importance of morbidity interactions with respect to multiple 
categories of healthcare costs. The specific technique that we use is the Chi-square automated 
interaction detection (CHAID) procedure that was first specified in Kass (1980) and developed into a 
command within Stata by Luchman (2013). CHAID is a recursive partitioning algorithm that builds a 
decision tree structure of split independent variables based on their statistical significance in relation 
to a dependent variable (Luchman 2013). We have chosen CHAID as the procedure within this paper 
as it is specifically designed for categorical variables, produces complex tree structures (as it allows 
for more than two splits) and reduces the likelihood of over-fitting (i.e. selecting predictors with more 
categories) by filtering out variables that are not related to the dependent variable using a statistical 
association test (i.e. a Chi-square specification). Refer to van Diepen and Franses (2006) and Loh 
(2011) for a discussion of these features of the CHAID procedure and how they differ in comparison 
to other classification and regression tree procedures. 
 
As the underlying recursive estimation procedure utilises ordered logit estimation, we have used the 
deciles of each type of healthcare cost as the dependent variables. After the procedure is complete we 
obtain a set of interaction groups that is based on a large number of possible combinations of the sixty 
morbidity dummy variables (coded to match the DDMG) that result in interaction groups with more 
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a few individuals and is imposed to prevent a large number of interactions being specified. In contrast, 
Buchner, Wasem, and Schillo (2017) set a similar threshold to 30 individuals and then relied on a 
minimal R² improvement per split of 0.0001 as it is the level used in the German risk adjustment 
model. van Veen et al. (2017) set this threshold to be between 415 and 862 individuals based on the 
smallest risk class size within the Dutch risk equalisation model that is the basis of their paper. 
 
It should be noted that our argument in favour of using interaction detection in this manner is similar 
to that used in Belloni, Chernozhukov, and Hansen (2014a) when discussing variable and functional 
form selection with high dimensional data. In that paper, Belloni, Chernozhukov, and Hansen (2014a) 
used a Least Absolute Shrinkage and Selection Operator (LASSO) approach to determine the 
variables and functional form selection for use in models of government seizure of private property, 
the effect of legalised abortion on crime and the effect of institutions on output. With hundreds of 
thousands of individuals in this data set, our data is high-dimensional in nature as the possible number 
of interaction variables using 60 morbidity dummy variables (with 0 and 1 as unique classifications) 
and a large order of interactions is extremely large. For example, with 120 morbidity classifications 
and 4 way interactions, the possible number of interaction variables is approximately 9 million. For a 
larger order of interactions, the possible number of interaction variables increases considerably.  
 
Upon discussing wide-ranging attitudes towards data mining, Belloni, Chernozhukov, and Hansen 
(2014a) stated that “data mining methods are relevant for learning about economic parameters where 
they are motivated, for example, by a desire to control properly for confounding variables” (Belloni, 
Chernozhukov, and Hansen 2014a). They note that research where the choice of variables is based on 
economic intuition alone, even though there were a large number of variable specifications that were 
possible, often resulted in the authors “wondering whether the correct variables and functional forms 
were chosen” (Belloni, Chernozhukov, and Hansen 2014a). With sixty morbidity groups and a very 
large number of interactions possible, we argue that our use of interaction detection should be deemed 
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Nevertheless, it is important to distinguish between data mining as a ‘fishing’ exercise used to choose 
a model specification that is solely based on goodness of fit and as a tool to investigate the complex 
relationship between cost and morbidity. Our use of the CHAID procedure is also motivated by a 
limited theoretical basis for identifying an exhaustive set of multimorbidity groups that are relevant to 
cost amplifications for four different categories of cost. 
2.3 Evaluating model performance within sub-samples 
When assessing model performance between Models 1, 2 and 3, we will focus on the adjusted R-
squared statistics to indicate how the models compare at an aggregate level for each percentile of the 
conditional distribution estimated. In order to evaluate whether including the morbidity interaction 
terms in the quantile regressions improves the fit of Model 3, we compute the coefficient of 
determination for the actual cost and estimated cost for the entire sample and selected sub-samples 
(defined below). An improvement in model performance coincides with a coefficient of determination 
that is higher when the morbidity interaction variables are included in the calculation of estimated 
cost. To measure this, we calculate the coefficient of determination for five samples. These are: i) the 
entire sample with non-zero healthcare costs; ii) those patients with two morbidities (comorbidity 
subsample); iii) those with three or more morbidities (multimorbidity subsample); iv) those who died 
in the year of interest (Death in 2010 subsample); and v) those who died during the next calendar year 
(Death in 2011 subsample). For each sub-sample, denoted by k for which k=1,…,5, we estimate two 
sets of costs for each of the four categories of healthcare costs using the estimated coefficients 
obtained from the third set of quantile regressions (i.e. Model 3). One set of cost estimates are 
computed with the relevant morbidity interaction terms or death dummy variables included in the 
computation of the estimated cost of healthcare, , while the other set of estimates is computed 
without the morbidity interaction variables or death dummy variables, . The two coefficients of 
determination, i.e. the squared correlation coefficients, for each set of estimated healthcare costs and 
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  (3) 
∑
∑ ∑
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with k being the index of the sub-sample of interest and h the type of healthcare cost. For each sub-
sample that is conditional on having the determining factor, k, it is expected that   when the 
inclusion of the variables provides additional information and enhances the estimation of the 
healthcare cost for that subsample group. Note that the case of  can occur and coincides 
with a reduction in the accuracy of predicting the healthcare cost for that subsample group. 
3 Data 
The data used in this study is part of the Sax Institute’s 45 and Up Study. Note that this is the same 
data source as that used in Ellis et al. (2013). The baseline survey (conducted between 2006 and 2009) 
is linked to administrative health data that provides rich detail on an individual’s utilisation of medical 
services, pharmaceutical prescriptions and hospitalisations. The 45 and Up Study recruited more than 
267,000 people aged 45 and over in New South Wales (NSW), which is located on the east coast of 
Australia.  Prospective participants were randomly sampled from the Department of Human Services 
(DHS) enrolment data base, which provides near complete coverage of the population. People aged 
greater than 80 years old and residents of rural and remote areas were oversampled (45 and Up Study 
Collaborators 2008). About 18% of those invited participated in the survey and these participants 
accounted for almost 11% of the NSW population aged 45 years and over. The baseline survey has 
been linked to data from the Medical Benefits Scheme (MBS), the Pharmaceutical Benefits Scheme 
(PBS), the NSW Admitted Patient Data Collection (APDC) and the Emergency Department Data 
Collection (EDDC). The MBS dataset covers the services funded by Medicare, Australia’s universal 
publicly funded system for medical services, which includes visits to GPs and specialists, as well as 
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The 45 and Up Study was approved by the University of New South Wales Human Research Ethics 
Committee (HREC). Participants’ consent was sought before linking the administrative data to the 
survey data. Linkage of the 45 and Up baseline survey data to the MBS and PBS data provided by the 
Department of Human Services was completed by the Sax Institute using a unique identifier. Linkage 
to the administrative data from the APDC and EDDC was conducted by the Centre for Health Record 
Linkage (CHeReL) with ethics approval from the NSW Population and Health Services Research 
Ethics Committee (PHSREC).  
 
The linkage of the 45 and Up Study to administrative data allows us to match the annual costs of 
healthcare to demographic variables and self-reported health status. These annual costs are Medicare 
funded medical services (Med. Serv.), pharmaceutical (Pharma), hospital (Hosp.) and total healthcare 
costs (Total). These total healthcare costs are not all inclusive1 as they are the aggregation of the 
medical services, pharmaceutical and hospital costs. Medical services costs are the expenditure on 
costs related to the MBS and include out-of-pocket costs. Pharmaceutical costs are the prices paid to 
the suppliers of PBS drugs. Both the MBS and PBS data report the costs that are directly used in the 
analysis. In the case of hospital costs, our administrative data includes information on the Australian 
Refined Diagnosis Related Groups (AR-DRG) codes for each hospital separation. This information is 
used to derive a cost per hospital episode based on the National Hospital Cost Data Collection 
(NHCDC) average cost estimates produced by the Independent Hospital Pricing Authority for public 
hospital patients (IHPA 2013). The Hospital Casemix Protocol (HCP) average cost estimates are used 
for private hospital patients (Dept of Health 2015, 2016).  
To account for varying complexities in the treatment of individual hospital episodes of care, we have 
adjusted the average costs associated with each AR-DRG code for each individual’s length of stay 
when it differed from the average length of stay used in the NHCDC and HCP. Equation five shows 
                                                 
1 The main types of healthcare costs that are excluded include dental services, optometry, allied health, non-
subsidised pharmaceuticals and other outpatient hospital services. Note that there are no individualised data on 
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the computation that we have made for each episode of hospital care to obtain the adjusted cost of 
hospitalisation ( ) for each diagnosis, d (which matches the AR-DRG code), and episode of 
care, e. This involved identifying the cost for each additional or lesser day of hospital stay in 
comparison to the average length of stay ( ). We did this by identifying the expenses that tend 
to be upfront costs and essential services that are likely to be incurred once or at the beginning of a 
hospital admission ( ). This includes the cost associated with critical care, operation rooms, 
emergency departments, special procedure suites and prostheses. These essential service costs, , 
are deducted from the total average cost of hospitalisation for each AR-DRG ( ) and this is divided 
by the average length of stay used in the cost schedules for public and private hospitalisations to 
obtain a daily add-on cost estimate. We obtain the adjusted average cost for the hospital patient’s 
episode of care by adding/subtracting the daily add-on cost for each of the days the individual had 
stayed in the hospital longer/shorter than the average length of stay for that AR-DRG code.  
 
⁄       (5) 
 
After establishing a cost associated with hospital admissions, all of the cost and administrative data 
have been aggregated to create annual variables for the calendar years between 2006 and 2011. In this 
paper we focus on the data from 2010 as it allows us to include variables that capture whether death is 
imminent and occurs in the current year or the next year (i.e. 2011). The analysis is conducted on the 
full cohort of the 45 and Up Study that had non-zero annual costs in the year 2010. As noted in Table 
1A, the dummy variables of sixty morbidity groups are coded using the DRG-10 and ATC codes from 
the APDC and PBS datasets. Table 1A also describes a range of control variables sourced from the 45 
and Up survey and these include a 5-point scale of self-reported health status, demographic, economic 
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4 Results 
4.1 Identification of morbidity interactions 
This section focuses on the results from the CHAID procedure that has been used to identify the 
morbidity interactions that are related to healthcare costs. While the results can be represented as a 
tree structure with a series of branches that are distinguished by zero and non-zero observations of the 
dummy variables selected by the procedure, we have converted these trees into interaction dummy 
variables for inclusion in the healthcare cost models. Tables 3A to 6A in the appendix present the 
morbidity interactions that were identified for four categories of healthcare costs using the CHAID 
procedure, respectively. As the CHAID procedure identifies interactions based on the existence and 
non-existence of morbidities, the rows in Tables 3A to 6A present a unique combination of ✓ and ✕ 
that coincide with whether the interaction group incorporates the existence or non-existence of that 
specific combination of morbidities. Tables 3A to 6A also includes the number of morbidity groups 
identified as being relevant to that interaction group and the number of coexisting morbidities, which 
coincides with the number of times ✓ appears. Note that when assessing the cost estimates associated 
with these interaction terms in section 4.3, the relevant figures (i.e. Figures 1 to 4) will include the 
specification of the relevant interaction groups that coincide with Tables 3A to 6A in the appendix. 
 
As the CHAID procedure selected these interactions using an ordered variable of the decile group of 
cost that each individual was in, an indication of the general costliness of each interaction group is 
provided in Tables 3A to 6A with the percent of individuals who had that morbidity interaction and 
were in the top decile of that healthcare cost distribution. The interaction group with the greatest 
proportion of individuals within the top decile of total healthcare costs (72%) coincided with 
individuals who had functional disorders of the digestive system, malignant neoplasm and bacterial 
infection or septicemia but not thrombo-embolic risk or disease (i.e. interaction group t24). The 
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coincides with malignant neoplasm, bacterial infection or septicemia and thrombo-embolic risk or 
disease (t32). The third greatest proportion of individuals within the top decile (64%) coincides with 
interaction group t31 and this group is comprised of those individuals who had heart failure, 
functional disorders of the digestive system, pain, bacterial infection or septicemia and thrombo-
embolic risk or disease but not malignant neoplasm. 
 
For pharmaceutical costs (Table 4A), the interaction group with the greatest proportion of individuals 
within the top decile (73%) coincided with a group of individuals who had diabetes mellitus, 
hyperlipidemia, reactive airway disease, diseases of esophagus and peptic ulcer as well as thrombo-
embolic risk and disease (p48). In the case of medical services costs (Table 5A), the corresponding 
group (61%) were those who had malignant neoplasm, bacterial infection or septicemia and thrombo-
embolic risk or disease (m32). In the case of hospital costs (Table 6A), there was no interaction group 
that coincided with more than 50% of individuals within the top decile. This implies that high hospital 
costs are not as well explained as other types of healthcare costs using morbidity interaction groups as 
explanatory variables. The results reveal that 40% of individuals with heart failure, functional 
disorders of the digestive system and thrombo-embolic risk or disease had hospitalisation costs that 
reached the top decile of the hospital cost distribution. Thirty percent of those with functional 
disorders of the digestive system, malignant neoplasm and bacterial infection or septicemia but not 
thrombo-embolic risk or disease were in the top decile of hospital costs. 
4.2 Model performance with and without morbidity interactions 
This section assesses the model performance that occurs with and without the interaction variables. 
Before focusing on the sub-sample analysis, we will review model performance for the whole sample 
using the adjusted R-square statistics. Table 1 contains the adjusted R-square statistics for the 
simultaneous-quantile regressions that were estimated for each type of healthcare cost and model 
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square statistics for Model 3 compared to Model 1 and Model 2. Note that assessing improvements in 
model performance is difficult without a benchmark to assess how large a difference should be for it 
to be assessed as notable. Note that Buchner, Wasem, and Schillo (2017) deemed an improvement in 
the overall adjusted R-square of 0.0038 to be a marginal improvement. Upon finding that the 
inclusion of interaction variables increased the R-square value of 0.2556 by between 0.008 and 
0.0178, van Veen et al. (2017) concluded that future studies should include interactions in risk-
equalisation models. Based on these studies we use improvements in model performance that are 
greater than 0.005 as a benchmark. These cases are bolded in Table 1.  
 
When comparing Model 3 to Model 2 the greatest improvements in the explanatory power of the 
models occurred within the medical services and hospital cost distributions. In the case of medical 
services, improvements occur across all percentiles. For hospital costs, the improvements coincide 
with the median, high and extremely high percentiles. Upon comparing Model 3 to Model 2, the 
estimation of pharmaceutical costs coincided with little improvement across all of the percentiles 
reviewed, except for the 10th percentile. However, when comparing Model 3 to Model 1 there are 
large improvements across all costs and percentiles. For example, a 2.6% to 8.9% improvement 
occurred at the median of the four cost distributions. In contrast to previous findings that morbidity 
count variables perform well in comparison to multimorbidity measures (Brilleman et al. 2014, Islam 
et al. 2014), these results show notable improvements in model performance associated with a 
morbidity dummy and interaction variable model (i.e. Model 3 compared to Model 1). This is 
especially the case for pharmaceutical costs with improvements in explaining the variations of cost of 
between 8.3% and 25.5%. Note that the importance of focusing on the entire distribution of costs is 
reflected in model improvements that are higher for the right tail of all four cost distributions with 
respect to the median and 10th percentile. For the extremely high points of the total healthcare, 
medical services and hospital cost distributions (i.e. 95th and 98th percentiles), improvements in 
explanatory power were between 7.0% and 8.0%. This compares to 1.0% and 2.6% for the lowest 





Multimorbidities and health care expenditure 
While the adjusted R-square statistics in Table 1 provide an overview of the differences in model 
performance at an aggregate level and indicates the conditional percentile estimates where overall 
model performance improved; it is important to assess model performance using appropriate sub-
samples to highlight the cases where there were notable improvements that would otherwise be 
hidden by the aggregation of many different individuals. Table 2 contains the differences in the 
coefficient of determination for alternative model specifications across selected subsamples for each 
category of healthcare cost. For the 10th and 50th percentiles of total healthcare costs, multimorbidity 
interaction variables were associated with the greatest improvement in the estimation of this 
healthcare cost. For the multimorbidity subsample the improvement was 2.8% for the 10th percentile 
and 2.0% for the 50th percentile. Notable improvements also coincide with the overall sample (2.2% 
for the 10th percentile and 1.6% for the 50th percentile) and the imminent death subsamples (between 
0.8% and 2%).  
 
For the estimates of extremely high healthcare costs (95th and 98th percentiles), the death dummy 
variables are associated with a decrease in model performance in relation to predicting total healthcare 
and hospital costs. So, while the parameter estimates associated with these death dummy variables are 
large and statistically significant (refer to Table 3 and Tables 7A to 10A for the cost estimates of these 
variables), the amount of variance in the costs associated with imminent death is also large and a 
dummy variable is insufficient to capture the wide dispersion of total healthcare and hospital costs 
that coincide with death. Note that we have not used the time to death variable specified in Felder, 
Werblow, and Zweifel (2010) and future work will control for the complexities associated with 
imminent death. Nevertheless, the death dummy variables do coincide with cost improvements for the 
medical services cost estimates within the imminent death subsamples. For the death in 2010 variable 
the improvement ranges from 2.9% to 5.7% depending upon the percentile estimate. In the case of 
death in the next year, the improvement ranges from 2.9% to 4.7%. In some cases, the estimates are 
negative (i.e. for pharmaceuticals and medical services) and reflects the nature of pharmaceutical and 
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the year has a strong influence on how high costs become. In contrast, hospital costs can be amplified 
in a relatively short amount of time and the death dummy variables are positive for all percentiles of 
total healthcare and hospital costs. 
 
The second segment of Table 2 contains the impact of including morbidity interaction variables on the 
estimates of pharmaceutical costs. The lack of a notable improvement is in line with the overall 
sample adjusted R-squared statistics shown in Table 1 for the comparison between Model 2 and 
Model 3. As noted in the introduction, prescribing practices have been found to be inapt at tackling 
the rise of multimorbidity. Limited improvements in estimating pharmaceutical costs through the 
inclusion of morbidity interaction variables is consistent with prescribing guidelines and practices that 
focus on individual diseases. In many cases, especially for the 10th percentile, there was a negative 
difference in the coefficients of determination and the model did not improve with the inclusion of 
morbidity interaction variables.  
 
The third segment of Table 2 reports the impact of including morbidity interaction variables on the 
estimates of medical services costs. Most of the improvements associated with multimorbidity 
variables are concentrated in the 10th and 50th percentiles. While the inclusion of death variables 
decreases model performance for the overall sample at the 90th, 95th and 98th percentiles, the inclusion 
of death variables improves the model estimates for the imminent death subsamples. As out-of-pocket 
costs are included in the medical services costs and doctors in Australia are free to set their own fees, 
medical services costs also reflect the willingness to pay for services by individual patients and 
exhibit considerable variation. In particular, wealthier patients typically pay higher prices for similar 
services than poorer patients do (Johar et al. 2016). For this reason, the morbidity interaction variables 
may not be capturing important drivers of high medical service costs. Rather, higher costs may be 
associated with the higher fees charged by esteemed specialists, or the greater willingness to pay for 
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subsamples suggest that in the last year of life there is an increased intensity of treatment by 
specialists dealing with health issues that have a notable risk of death. However, negative estimates 
for some percentile estimates show that timing matters and that there is great variability in medical 
services costs in the last two years of life. Another reason for the importance of imminent death is 
likely to be the intensity of the use of services related to at-home care for the terminally ill and the 
provision of palliative care outside of hospital in the final weeks of life. 
 
The last segment of Table 2 contains the impact of including morbidity interaction variables on the 
estimates of hospital costs and in this case the improvements associated with multimorbidity variables 
occur for the 10th and 50th percentiles. The inclusion of death variables reduces the performance of 
model estimates across all of the five samples and this reduction becomes larger at the right tail of the 
hospital cost distribution. This is likely to be related to the large variation in the costliness of the last 
year of life, which will depend on the cause of death and/or the types of treatments and services used 
within hospital or as part of at-home care. 
4.3 Cost estimates associated with the morbidity interaction and death 
variables 
This section focuses on the cost estimates associated with the interaction groups for the 50th, 90th, 95th 
and 98th percentiles of each category of healthcare cost. These cost estimates are separated into the 
components attributed to the regression’s intercept, the sum of costs associated with each of the 
relevant individual morbidity groups and the cost amplification that coincides with the morbidity 
interaction variables2. Note that Tables 7A to 10A in the appendix provide the parameter estimates 
used to calculate the costs estimates presented in Figures 1 to 4. Figure 1 contains the cost estimates 
                                                 
2 In some cases, the cost estimate associated with the interaction variable is negative and for these cases we have 
adjusted the cost associated with the intercept (or individual morbidity groups) so that the correct aggregate cost is 
shown on the y axis. The interpretation of interaction variables with a negative cost estimate should be conducted in 
relation to the other components of cost (specifically the intercept). This then captures cases where the interaction 
does not tend to coincide with extremely high costs in comparison to other morbidity classifications. This is evident 
as the incidence of negative estimates tends to occur for the 90th, 95th and 98th percentile estimates but not the 





Multimorbidities and health care expenditure 
for total healthcare costs across four percentiles (i.e. the 50th, 90th, 95th and 98th percentiles). Notable 
differences in the cost amplification associated with the morbidity interaction groups3 occur for each 
percentile reviewed. In the majority of cases, we observe that the largest cost amplifications tended to 
coincide with multimorbidity groups rather than comorbidity groups. For the median of total 
healthcare costs, these were interaction groups t24, t31 and t32. Note that for t24, the cost 
amplification was 60% of the total sum of the estimated costs and 1.6 times larger than the individual 
morbidity group cost component. The equivalent numbers for t31 and t32 are 59% (1.6 times larger) 
and 56% (1.4 times larger), respectively. While the costs associated with the morbidity interactions 
tend to increase for the higher percentiles, their magnitude in comparison to the sum of the costs 
associated with the individual morbidity estimates tends to diminish. Nevertheless, the largest 
interaction cost estimate for total healthcare costs was over $19,000 and this coincided with the 90th 
percentile estimate of multimorbidity group t31. However, this interaction cost estimate was smaller 
than the individual morbidity component of the estimated costs. Multimorbidity group t31 are those 
individuals who had heart failure, functional disorders of the digestive system, pain, bacterial 
infection or septicemia and thrombo-embolic risk or disease but not malignant neoplasm. Note that 
the aforementioned cases of cost amplification (i.e. t24, t31 and t32) correspond to the three 
interaction groups with the highest proportion of individuals within the top decile of total healthcare 
cost. 
 
In contrast to the cases of total healthcare and hospital costs, the cost amplification that occurs for 
pharmaceutical and medical services costs are relatively moderate. Figure 2 and 3 contain the cost 
estimates for pharmaceuticals and medical services costs. For the 50th percentile, the largest 
amplification of cost in terms of the relative size of the morbidity interaction estimate is 62% for 
pharmaceutical costs and 54% for medical services costs. These cases are attributed to multimorbidity 
groups p46 (with a cost amplification of $801) and m32 (with a cost amplification of $1,344). The 
                                                 
3 For the morbidity groups that are included and excluded in these morbidity interaction groups we refer the reader 
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largest interaction cost estimate for pharmaceutical costs occurs at the 98th percentile with the 
interaction estimate for p43. This corresponds to an increase in pharmaceutical costs of $1608. For 
medical services costs the largest interaction cost estimate occurs at the 98th percentile with m29 
having a cost estimate associated with the interaction variable of $5701.  
 
For hospital costs, the estimates for the 50th percentile show a large cost amplification for 
multimorbidity group h9 and h18. These cost amplifications are equivalent to $4325 and $5104, 
respectively. In the case of multimorbidity group h9, this cost amplification is associated with 
functional disorders of the digestive system, malignant neoplasm and bacterial infection or septicemia 
but not thrombo-embolic risk or disease. In the case of multimorbidity group h18, this cost 
amplification is associated with heart failure, functional disorders of the digestive system and 
thrombo-embolic risk or disease. Within this category of cost, there are a range of cases where the 
interaction cost estimate is negative, however these need to be considered in relation to the large 
hospital cost estimates associated with the individual morbidity groups at the extremely high cost 
points of the distribution. 
 
Table 3 contains the cost estimates associated with the age, BMI and death dummy variables included 
in the third model. Note that these cost estimates for age, BMI and imminent death have been 
computed with morbidity dummy and interaction variables included in the model (i.e. M3). The 
largest death related cost estimates are concentrated in the hospital cost and total healthcare cost 
models. For pharmaceuticals and medical services, the death related cost estimates are negative or less 
than a few thousand dollars. From this, it seems that hospital costs are those most amplified with 
respect to time to death. However, it is of interest to note that the cost estimates related to age are still 
quite large for the high (i.e. the 90th percentile) and extremely high (i.e. the 95th and 98th percentiles) 
points of the hospital cost distribution. The estimates related to the death dummy variables are large, 
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subsamples. Note that this may be due to correlation with morbidity variables and/or the interaction 
variables. While we adjusted the DRG costs using an individual’s length of stay and this data is the 
best available at the time of writing, it does not include the heterogeneity that hospital-specific data 
for the corresponding episodes is likely to include. In future research, we hope to gain access to 
Independent Hospital Pricing Authority (IHPA) hospital data that captures this heterogeneity and will 
reveal how large hospital costs do become. 
 
Table 3 also includes the estimates that correspond to BMI dummy variables. Notable differences in 
cost estimates across the healthcare category and the percentiles used. For total healthcare costs, the 
largest estimates are associated with those who are obese and the 90th, 95th and 98th percentile 
estimates. However, for hospital costs the largest cost estimates coincide with underweight 
individuals and the 95th and 98th percentiles. For those admitted to hospital, being underweight is 
likely to be related to the type of morbidity they have or the treatment they are undergoing. While the 
U-shaped relationship between BMI and expenditure found by Buchmueller and Johar (2015) using 
similar data linked to the 45 and Up study for the period between 2006 to 2009 does occur at least 
once in the cost estimates of each healthcare category, it does not always appear across all percentiles. 
Pharmaceutical costs are the category of healthcare where a U-shaped relationship is least notable. 
This is consistent with the results of Buchmueller and Johar (2015) when they focus on different types 
of healthcare costs.   
5 Conclusion 
Within this paper, we have assessed whether morbidity interaction variables improve model 
performance in comparison to models that only have morbidity dummy variables or morbidity count 
variables using simultaneous quantile regressions. This was motivated by previous research that found 
that morbidity count variables outperformed more complicated morbidity measures (Brilleman et al. 
2014, Islam et al. 2014). In contrast to these studies, we find that models that include morbidity 
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number of coexisting morbidities. This is especially the case for the right tail of the total, medical 
services and hospital cost distributions (i.e. 90th, 95th and 98th percentiles) and all five points of the 
pharmaceutical cost distribution. Upon focusing on the conditional estimates of the 10th, 50th, 90th, 95th 
and 98th percentiles we find that notable cost amplifications coincide with multimorbidity rather than 
comorbidity.  
 
Our results suggest that further focus on multiple points of healthcare cost distributions will assist in 
making accurate adjustments for risk that are relevant to the development of payments systems. One 
of the important findings of this research is that thrombo-embolic risk or disease, malignant neoplasm, 
hyperlipidemia, diseases of esophagus and peptic ulcer, pain and bacterial infection or septicemia are 
the morbidities to focus on when investigating multimorbidities as important determinants of costly 
healthcare. Many of these morbidities are associated with the treatment of acute diseases and, for 
malignant neoplasm, the management of adverse treatment effects (i.e. bacterial infection after 
chemotherapy). This implies that a substantial number of patients with very high healthcare costs are 
suffering from unintended effects of treatment and that the health system’s ability to reduce such 
issues will have a substantial impact on costs.  
 
While the availability of large data sets is becoming more common, studies using this type of data 
need to adapt and adopt techniques suited to the complexities of ‘big data’. Future research should 
continue to explore the full distribution of healthcare costs and go beyond a focus on estimating the 
mean (de Meijer et al. 2013, Jones, Lomas, and Rice 2015). As the use of large administrative data is 
likely to result in data of a high-dimensional nature, automated data driven techniques are expected to 
be increasingly common in empirical economics. Belloni et al. (2012), Belloni, Chernozhukov, and 
Hansen (2014a), Belloni, Chernozhukov, and Hansen (2014b), Einav and Levin (2014), Varian 
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examples that have recently employed or have advocated for the use of automated data driven 
techniques within the analysis of large data sets.  
 
An important extension of this research will be confirming that similar results hold using other 
samples and morbidity classifications. In addition, it will be important to establish that similar 
interactions are found using CHAID and other interaction detection techniques. Epidemiological 
studies will also be needed to identify the morbidity specific determinants of costly healthcare that are 
behind the importance of these interaction effects. Our intention upon documenting the full range of 
interaction groups in Tables 3A to 6A within the appendix was, in part, to facilitate further research 
that investigates the underlying determinants driving the cost amplifications associated with these 
interaction groups in different settings.  
 
While we include death dummy variables in our models of healthcare costs, we do not precisely 
account for an individual’s time to death. Nevertheless, our results for medical services and hospital 
costs indicate that there is more work to be done on disentangling why some people have costly 
deaths and others do not. Previous research has found that time to death was an important driver of 
healthcare costs, however these results indicate that a simple variable capturing whether someone dies 
in the current year or the next does not improve the performance of hospital cost models. It is 
plausible that differences in the incidence and intensity of at-home care and hospital provided 
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10 50 90 95 98 
Total 
healthcare cost 
Morbidity dummy variables 
and interactions 
M3 
0.154 0.238 0.379 0.420 0.441 
Difference with respect to M1 0.026 0.039 0.076 0.078 0.078 
Difference with respect to M2 0.003 0.005 0.005 0.002 0.002
Morbidity dummy variables 
without interactions
M2 0.151 0.233 0.374 0.418 0.439 
Morbidity count variable M1 0.128 0.199 0.303 0.342 0.363
Pharmaceutical 
cost 
Morbidity dummy variables 
and interactions 
M3 
0.213 0.320 0.345 0.377 0.433 
Difference with respect to M1 0.083 0.089 0.131 0.185 0.255 
Difference with respect to M2 0.009 0.004 0.002 0.002 0.001
Morbidity dummy variables 
without interactions
M2 0.204 0.316 0.343 0.375 0.432 
Morbidity count variable M1 0.130 0.231 0.214 0.192 0.178
Medical 
services cost 
Morbidity dummy variables 
and interactions 
M3 
0.096 0.184 0.280 0.311 0.347 
Difference with respect to M1 0.012 0.026 0.057 0.070 0.080 
Difference with respect to M2 0.007 0.017 0.036 0.041 0.044
Morbidity dummy variables 
without interactions
M2 0.089 0.167 0.244 0.270 0.303 
Morbidity count variable M1 0.084 0.158 0.223 0.241 0.267
Hospital cost 
Morbidity dummy variables 
and interactions 
M3 
0.022 0.105 0.247 0.265 0.281 
Difference with respect to M1 0.009 0.029 0.071 0.071 0.070 
Difference with respect to M2 0.002 0.008 0.017 0.028 0.040
Morbidity dummy variables 
without interactions
M2 0.020 0.097 0.230 0.237 0.241 
Morbidity count variable M1 0.013 0.076 0.176 0.194 0.211
Note: we highlight the larger improvements in model performance by bolding the differences in the adjusted R-square 
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Table 2 – Improvement in the coefficient of determination 
Model Sample 
Percentile 


















































































































































































(n = 267,086) 
 0.000   0.022   0.001   0.000   0.016   0.000   0.001   0.002  -0.002 -0.000  0.001  -0.007  -0.001  -0.000  -0.015  
Comorbidity 
subsample  
(n = 29,753) 
 0.003   -     0.001   0.001   -     0.001   0.003   -     0.002   0.003   -    -0.002   0.003   -    -0.011  
Multimorbidity 
subsample  
(n = 106,032) 
 0.000   0.028   0.002  -0.000   0.020   0.003   0.000   0.001   0.001  -0.001  0.001  -0.005  -0.002  -0.000  -0.014  
Death in 2010 
subsample 
(n = 3,000) 
 0.002   0.020   0.000   0.002   0.017  -0.000   0.003  -0.001  -0.004  0.001  -0.002  -0.011   0.000  -0.001  -0.018  
Death in 2011 
subsample 
(n = 3,399) 
-0.000   0.018   0.002  -0.000   0.008   0.004   0.000  -0.009   0.003  -0.001 -0.005  -0.005  -0.001  -0.001  -0.014  
Pharm. 
Overall sample 
(n = 182,484) 
-0.003  -0.010  -0.004  -0.001  -0.000  -0.002   0.000   0.005   0.002   0.000   0.005   0.006   0.000   0.004   0.006  
Comorbidity 
subsample 
(n = 29,424) 
 0.000   -    -0.005   0.001   -    -0.004   0.002   -    -0.002  0.001   -     0.001   0.001   -     0.001  
Multimorbidity 
subsample 
(n = 105,957) 
-0.004  -0.013  -0.003  -0.001  -0.002  -0.002  -0.000   0.004   0.001  -0.000  0.003   0.004  -0.000   0.002   0.004  
Death in 2010 
subsample 
(n = 2,622) 
-0.003  -0.011  -0.007  -0.001  -0.001  -0.008  -0.000   0.002  -0.005  0.000   0.002  -0.002   0.000   0.001  -0.002  
Death in 2011 
subsample 
(n = 3,022) 




(n = 253,765) 
 0.001   0.012   0.007   0.001   0.006  -0.008  -0.001   0.003  -0.042 -0.001  0.002  -0.050  -0.001   0.001  -0.067  
Comorbidity 
subsample 
(n = 29,552) 
 0.004   -     0.011   0.002   -    -0.013  -0.000   -    -0.022  0.001   -    -0.023   0.001   -    -0.028  
Multimorbidity 
subsample 
(n = 105,866) 
 0.002   0.017   0.017   0.001   0.009   0.014  -0.001   0.004   0.002  -0.001  0.003  -0.001  -0.002   0.000  -0.009  
Death in 2010 
subsample 
(n = 2,783) 
 0.001   0.018   0.029   0.001   0.009   0.042   0.001   0.010   0.054   0.001   0.007   0.055   0.001   0.006   0.057  
Death in 2011 
subsample 
(n = 3,284) 
 0.000   0.013   0.029  -0.000   0.004   0.040  -0.001  -0.010   0.046  -0.001 -0.015   0.047  -0.001  -0.020   0.046  
Hosp. 
Overall sample 
(n = 72,287) 
 0.004   0.011   0.005  -0.002   0.006  -0.003   0.005   0.003  -0.006  0.003   0.002  -0.016   0.001   0.001  -0.023  
Comorbidity 
subsample 
(n = 8,234) 
 0.000   -     0.008   0.002   -     0.002   0.007   -    -0.006  0.003   -    -0.025   0.002   -    -0.032  
Multimorbidity 
subsample 
(n = 45,352) 
 0.004   0.012   0.003  -0.002   0.008  -0.005   0.006   0.004  -0.009  0.003   0.002  -0.018   0.001   0.001  -0.024  
Death in 2010 
subsample 
(n = 2,516) 
 0.002   0.006  -0.001  -0.001   0.003  -0.002  -0.001   0.002  -0.006 -0.001  0.002  -0.010   0.000   0.001  -0.009  
Death in 2011 
subsample 
(n = 2,170) 
-0.000   0.004   0.002  -0.004  -0.005   0.004   0.001   0.000  -0.000 -0.001  0.000  -0.004  -0.000   0.001  -0.008  
Note: we highlight the larger improvements in model performance by bolding the differences that are greater than 0.005. Large 
decreases in model performance are highlighted when the differences are less than -0.005. 
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Figure 1 – Annual total healthcare costs associated with morbidities and morbidity interactions 
  






































Morbidity and morbidity interaction groups index 
Morbidity groups Interaction groups 
Diabetes (3) 
Heart failure (13) 
Hyperlipidemia (29) 
Functional disorders of the digestive system (43) 
Ischemic heart diseases (51) 
Diseases of esophagus and peptic ulcer (53) 
Malignant neoplasm (54) 
Pain (56) 
Bacterial infection or septicemia (58) 
Thrombo-embolic risk or disease (59) 
Comorbidity interaction groups: 
t7 (3=1, 29=1, 36=0, 53=0, 54=0, 55=0, 56=0, 58=0, 59=0) 
t10 (29=1, 53=1, 54=0, 55=0, 56=0, 58=0, 59=0) 
t14 (29=0, 53=1, 54=0, 56=1, 58=0, 59=0) 
t15 (29=1, 54=0, 56=1, 58=0, 59=0) 
t16 (54=1, 56=1, 58=0, 59=0) 
t18 (29=0, 53=0, 54=0, 56=1, 58=1, 59=0) 
t19 (29=1, 53=0, 54=0, 58=1, 59=0) 
t20 (53=1, 54=0, 56=0, 58=1, 59=0) 
t23 (43=0, 54=1, 58=1, 59=0) 
t26 (51=0, 54=0, 56=0, 58=1, 59=1) 
Multimorbidity interaction groups: 
t21 (43=0, 53=1, 54=0, 56=1, 58=1, 59=0) 
t22 (43=1, 53=1, 54=0, 56=1, 58=1, 59=0) 
t24 (43=1, 54=1, 58=1, 59=0) 
t27 (51=1, 54=0, 56=0, 58=1, 59=1) 
t28 (43=0, 51=0, 54=0, 56=1, 58=1, 59=1) 
t29 (43=0, 51=1, 54=0, 56=1, 58=1, 59=1) 
t30 (13=0, 43=1, 54=0, 56=1, 58=1, 59=1) 
t31 (13=1, 43=1, 54=0, 56=1, 58=1, 59=1) 
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Figure 2 – Annual pharmaceutical costs associated with morbidities and morbidity interactions 




























Morbidity and morbidity interaction groups index 
Morbidity groups Interaction groups 
Diabetes mellitus (3) 
Mood [affective] disorders (6) 
Hypertensive disease (11) 
Hyperlipidemia (29) 
Reactive airway disease (52) 
Diseases of esophagus & peptic ulcer (53) 
Inflam. polyarthritis & connective tissue disord. (55) 
Pain (56) 
Bacterial infection or septicemia (58) 
Thrombo-embolic risk or disease (59) 
                Multimorbidity interaction groups: 
p14 (6=1, 29=0, 53=1, 56=1, 58=0, 59=0) 
p15 (29=0, 53=1, 56=1, 58=0, 59=0) 
p16 (6=1, 29=0, 53=0, 56=1, 58=0, 59=0) 
p19 (29=0, 52=1, 53=1, 56=1, 58=0, 59=0) 
p21 (3=1, 29=1, 53=0, 56=0, 58=1, 59=0) 
p22 (29=1, 53=1, 56=0, 58=1, 59=0) 
p24 (6=0, 29=0, 52=1, 53=0, 56=1, 58=1, 59=0) 
p26 (3=0, 29=1, 52=0, 53=0, 56=1, 58=1, 59=0) 
p27 (3=0, 29=1, 52=1, 53=0, 56=1, 58=1, 59=0) 
p28 (3=1, 29=1, 53=0, 56=1, 58=1, 59=0) 
p29 (29=0, 52=0, 53=1, 56=1, 58=1, 59=0) 
p30 (29=0, 52=1, 53=1, 56=1, 58=1, 59=0) 
p31 (3=0, 6=0, 29=1, 52=0, 53=1, 56=1, 58=1, 59=0) 
p32 (3=0, 6=1, 29=1, 52=0, 53=1, 56=1, 58=1, 59=0) 
p33 (3=0, 29=1, 52=1, 53=1, 56=1, 58=1, 59=0) 
p39 (3=0, 29=1, 52=1, 53=0, 59=1) 
p40 (3=1, 29=1, 53=0, 59=1) 
p42 (29=0, 53=1, 55=0, 56=1, 59=1) 
p44 (3=0, 6=0, 29=1, 52=0, 53=1, 59=1) 
p45 (3=0, 6=1, 29=1, 52=0, 53=1, 59=1) 
p46 (3=0, 29=1, 52=1, 53=1, 59=1) 
p47 (3=1, 29=1, 52=0, 53=1, 59=1) 
p48 (3=1, 29=1, 52=1, 53=1, 59=1) 
Interaction groups 
Comorbidity interaction groups: 
p6 (3=0, 6=1, 29=1, 53=0, 54=0, 56=0,58=0, 59=0) 
p7 (3=1, 29=1, 53=0, 54=0, 56=0, 58=0, 59=0) 
p8 (29=1, 53=1, 54=0, 56=0, 58=0, 59=0) 
p11 (6=1, 29=0, 53=0, 56=1, 58=0, 59=0) 
p12 (29=1, 53=0, 56=1, 58=0, 59=0) 
p13 (6=0, 29=0, 53=1, 56=1, 58=0, 59=0) 
p17 (29=0, 52=1, 53=0, 56=0, 58=1, 59=0) 
p18 (29=0, 52=0, 53=1, 56=0, 58=1, 59=0) 
p20 (3=0, 29=1, 53=0, 56=0, 58=1, 59=0) 
p23 (6=0, 29=0, 52=0, 53=0, 56=1, 58=1, 59=0) 
p36 (11=0, 29=0, 53=0, 56=1, 59=1) 
p37 (11=1, 29=0, 53=0, 59=1) 
p38 (3=0, 29=1, 52=0, 53=0, 59=1) 
p41 (29=0, 53=1, 55=0, 56=0, 59=1) 
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Figure 3 – Annual medical services costs associated with morbidities and morbidity interactions 




























Morbidity and morbidity interaction groups index 
Morbidity groups Interaction groups 
Diabetes mellitus (3) 
Other mental and behavioral disorders (7) 
Conduction disord. & cardiac arrhythmias (12) 
Hyperlipidemia (29) 
Eye inflammation (36) 
Functional disorders of the digestive system (43) 
Ischemic heart diseases (51) 
Diseases of esophagus and peptic ulcer (53) 
Malignant neoplasm (54) 
Inflam. polyarthritis & connective tissue disord. (55) 
Pain (56) 
Bacterial infection or septicemia (58) 
Thrombo-embolic risk or disease (59) 
                Multimorbidity interaction groups: 
m15 (7=1, 29=0, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) 
m16 (29=1, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) 
m17 (3=0, 36=0, 43=0, 53=1, 54=0, 55=0, 56=1, 58=1, 59=0) 
m18 (3=1, 36=0, 43=0, 53=1, 54=0, 55=0, 56=1, 58=1, 59=0) 
m19 (36=0, 43=0, 53=1, 54=0, 55=1, 56=1, 58=1, 59=0) 
m20 (36=0, 43=1, 53=1, 54=0, 56=1, 58=1, 59=0) 
m21 (36=1, 54=0, 56=1, 58=1, 59=0) 
m22 (43=0, 54=1, 56=1, 58=1, 59=0) 
m23 (43=1, 54=1, 56=1, 58=1, 59=0) 
m25 (12=0, 36=0, 43=0, 51=0, 53=0, 54=0, 55=0, 56=1, 58=1, 
59=1) 
m26 (12=0, 36=0, 43=0, 51=0, 53=1, 54=0, 55=0, 56=1, 58=1, 
59=1) 
m27 (12=0, 36=0, 43=0, 51=1, 54=0, 55=0, 56=1, 58=1, 59=1) 
m28 (12=0, 36=0, 43=0, 54=0, 55=1, 56=1, 58=1, 59=1) 
m29 (12=1, 36=0, 43=0, 54=0, 56=1, 58=1, 59=1) 
m30 (36=0, 43=1, 54=0, 56=1, 58=1, 59=1) 
m31 (36=1, 54=0, 56=1, 58=1, 59=1) 
m32 (54=1, 58=1, 59=1) 
Interaction groups 
Comorbidity interaction groups: 
m5 (36=0, 53=1, 54=0, 56=1, 58=0, 59=0)  
m6 (36=1, 54=0, 56=1, 58=0, 59=0) 
m10 (29=1, 36=0, 53=0, 54=0, 56=0, 58=1, 59=0) 
m11 (36=0, 53=1, 54=0, 56=0, 58=1, 59=0) 
m12 (36=1, 54=0, 56=0, 58=1, 59=0) 
m13 (54=1, 56=0, 58=1, 59=0) 
m14 (7=0, 29=0, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) 
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Figure 4 – Annual hospital costs associated with morbidities and morbidity interactions 



























Morbidity and morbidity interaction groups index 
Morbidity groups Interaction groups 
Heart failure (13) 
Hyperlipidemia (29) 
Functional disorders of the digestive system (43) 
Ischemic heart diseases (51) 
Malignant neoplasm (54) 
Pain (56) 
Bacterial infection or septicemia (58) 
Thrombo-embolic risk or disease (59) 
Comorbidity interaction groups: 
h5 (13=0, 43=0, 54=0, 56=1, 58=1, 59=0) 
h7 (13=1, 54=0, 58=1, 59=0) 
h8 (43=0, 54=1, 58=1, 59=0) 
h11 (13=0, 29=0, 51=0, 54=0, 56=1, 59=1) 
h12 (13=0, 29=1, 51=0, 54=0, 58=0, 59=1) 
h15 (13=0, 51=1, 54=0, 59=1) 
h16 (13=0, 54=1, 59=1) 
h17 (13=1, 43=0, 59=1) 
                Multimorbidity interaction groups: 
h6 (13=0, 43=1, 54=0, 56=1, 58=1, 59=0) 
h9 (43=1, 54=1, 58=1, 59=0) 
h13 (13=0, 29=1, 51=0, 54=0, 56=0, 58=1, 59=1) 
h14 (13=0, 29=1, 51=0, 54=0, 56=1, 58=1, 59=1) 
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Table 3 – Cost estimates related to age, weight and death variables 
Model Variables 
Percentile 
10 50 90 95 98 
Total 
Constant (incl. ≥ 75) 13.06 430.50 4,127.58 8,481.36  16,487.08  
Age: 45-49 -16.70 -120.44 -1,435.12 -3,333.33  -7,420.78  
Age: 50-54 -4.74 -74.22 -1,263.12 -3,192.68  -7,461.34  
Age: 55-59 4.49 -15.91 -904.78 -2,472.51  -5,885.02  
Age: 60-64 9.51 24.76 -592.26 -1,949.78  -5,034.04  
Age: 65-69 -1.30 2.63 -728.14 -2,273.99  -5,156.66  
Age: 70-74 15.51 39.39 -555.27 -1,754.92  -3,582.11  
BMI - Underweight -30.05 -69.08 -66.31 752.28   828.70  
BMI - Overweight 1.72 -0.64 -19.37 -63.28   18.86  
BMI - Obese Class 1 1.98 18.06 287.58 509.11   942.43  
BMI - Obese Class 2 13.03 65.75 683.08 946.46   2,601.98  
BMI - Obese Class 3 25.58 90.73 384.96 793.92   2,431.37  
Death in 2010 116.93 11,625.07 31,878.01 41,305.39   56,024.46  
Death in 2011 246.49 3,653.90 20,486.50 25,279.99   29,953.11  
Pharm. 
Constant (incl. ≥ 75) -105.06 17.96 451.53 670.50   1,136.69  
Age: 45-49 -43.04 -97.69 -157.03 -240.97  -419.03  
Age: 50-54 -39.16 -85.01 -139.39 -207.01  -336.31  
Age: 55-59 -39.03 -72.18 -123.44 -191.68  -317.01  
Age: 60-64 -29.14 -50.27 -91.13 -141.29  -248.05  
Age: 65-69 -11.26 -7.91 -27.28 -84.64  -249.29  
Age: 70-74 3.89 25.03 21.48 -22.79  -156.24  
BMI - Underweight -16.30 -8.37 10.85 35.18  -12.99  
BMI - Overweight 15.50 23.18 32.05 24.61   29.85  
BMI - Obese Class 1 12.36 35.53 51.63 43.42   42.67  
BMI - Obese Class 2 15.22 59.77 67.97 107.11   135.24  
BMI - Obese Class 3 33.11 102.77 147.57 155.95   59.24  
Death in 2010 -517.00 -653.80 -615.62 -696.17  -785.47  
Death in 2011 -1.01 169.78 905.94 1,531.13   3,675.42  
Med. Serv. 
Constant (incl. ≥ 75) 130.33 564.74 2,048.40 2,910.30   4,567.92  
Age: 45-49 -78.48 -240.13 -568.42 -712.13  -1,115.92  
Age: 50-54 -69.94 -205.68 -485.53 -598.38  -965.10  
Age: 55-59 -55.72 -154.68 -329.90 -375.92  -489.29  
Age: 60-64 -48.18 -113.59 -152.75 -90.88  -178.52  
Age: 65-69 -56.93 -128.67 -159.45 -121.43  -167.91  
Age: 70-74 -43.97 -81.81 -71.12 17.84  -114.84  
BMI - Underweight -13.00 -11.44 27.86 142.23   118.86  
BMI - Overweight -5.25 -11.31 -19.97 -76.50  -139.04  
BMI - Obese Class 1 4.56 4.96 84.32 124.41   132.32  
BMI - Obese Class 2 6.04 23.94 155.39 275.36   448.28  
BMI - Obese Class 3 7.44 2.86 90.45 242.69   352.78  
Death in 2010 -435.21 -621.83 -487.91 -232.34   1,083.99  
Death in 2011 -43.09 152.96 1,003.94 2,137.52   2,865.12  
Hosp. 
Constant (incl. ≥ 75) 1,288.27 3,034.48 15,246.14 24,893.88   40,660.58  
Age: 45-49 -20.22 -296.65 -4,441.49 -7,324.74  -9,326.13  
Age: 50-54 -24.97 -415.69 -4,375.62 -7,922.06  -11,615.05  
Age: 55-59 -17.75 -340.21 -3,388.56 -5,481.91  -7,923.40  
Age: 60-64 -21.05 -225.92 -2,552.23 -3,470.21  -3,125.14  
Age: 65-69 -50.82 -422.86 -2,654.50 -3,696.52  -4,399.41  
Age: 70-74 -44.68 -232.09 -1,563.20 -2,712.41  -1,787.29  
BMI - Underweight -5.95 -76.29 1,458.13 5,558.97   5,311.61  
BMI - Overweight -0.16 5.56 -107.77 -181.27   449.88  
BMI - Obese Class 1 4.00 177.79 521.51 526.59  -178.35  
BMI - Obese Class 2 33.44 385.28 1,390.28 2,847.10   516.36  
BMI - Obese Class 3 -3.21 78.15 1,401.62 844.45  -866.49  
Death in 2010 2,710.33 13,081.06 29,974.96 36,836.50   50,140.64  
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7 Appendix 
 
Table 1A – Specification of the explanatory variables in the models of healthcare costs  
Type of variable Description Model one Model two Model three 
Count variable of 
coexisting 
morbidities 
Count variable of the number of 
coexisting morbidities using the 
morbidity classification mentioned 
below.  
✓ ✕ ✕ 
Dummy variables of 
morbidity groups  
Coded using DRG-10 and ATC codes – 
refer to Halfon et al. (2013) for the full 
specification. The full list of morbidity 
groups is included in the appendix in 
Table 2A. 
✕ ✓ ✓ 





These are a set of dummy variables that 
capture selected interaction groups from 
the results of the CHIAD analysis that 
are unique for each type of healthcare 
cost. The full sets of interactions 
identified using the CHAID procedure 
are included in the appendix in Tables 
3A to 6A. 
✕ ✕ ✓ 
Dummy variables of 
self-reported health 
status  
Dummy variables created using the five 
point scale variable from the baseline 
questionnaire of the 45 and Up study. 
For further details refer to 45 and Up 
Study Collaborators (2011). 





Selected variables included in the 
baseline questionnaire and described in 
45 and Up Study Collaborators (2011). 
The selection of these variables is based 
on the models utilised in Ellis et al. 
(2013) and Jones, Lomas, and Rice 
(2015). These variables include an 
individual’s demographics, income, 
labour force status and lifestyle habits 
(including identifying those who 
smoke, are underweight or obese and 
consume high levels of alcohol).  
✓ ✓ ✓ 
Dummy variables 
for the case were an 
individual dies in 
the same year 
(2010) or the 
subsequent year 
(2011) 
Month and year of death are sourced 
from linked data provided by the NSW 
Registry of Births, Deaths and 
Marriages. This has been used to create 
dummy variables that indicate whether 
death occurred in 2010 or 2011, 
respectively. 
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Table 2A – Morbidity groups and matching morbidity IDs 
Morbidity Groups Morbidity ID
Tuberculosis 1 
Human immunodeficiency virus disease 2 
Diabetes mellitus 3 
Mental and behavioral disorders due to alcohol 4 
Schizophrenia, schizotypal and delusional disorders 5 
Mood [affective] disorders 6 
Other mental and behavioral disorders 7 
Alzheimer’s disease 8 
Multiple sclerosis 9 
Epilepsy 10 
Hypertensive disease 11 
Conduction disorders and cardiac arrhythmias  12 
Heart failure 13 
Crohn’s disease and ulcerative colitis 14 
Infections of the skin and subcutaneous tissue 15 
Hyperplasia of prostate 16 
Inflammatory diseases of female pelvic organs 17 
Poisoning by drugs and biological substances 18 
Paludism 19 
Parasitosis 20 
Hepatitis B or C 21 
Viral diseases 22 
Anemia – nutritional 23 
Non nutritional anemia 24 
Neutropenia 25 
Thyroid disorders 26 
Other endocrine, nutritional and metabolic diseases 27 
Obesity 28 
Hyperlipidemia 29 
Mental and behavioral disorders due to opioids 30 
Mental and behavioral disorders due to tobacco 31 
Migraine 32 
Parkinson’s disease 33 
Conjunctivitis 34 
Glaucoma 35 
Eye inflammation 36 
Disorders of external ear 37 
Vertigo 38 
Influenza 39 
Other acute upper respiratory infections 40 
Other diseases of upper respiratory tract – allergy 41 
Hemorrhoids 42 






Transplanted organ status 49 
Gastroenteritis of presumed infectious origin 50 
Ischemic heart diseases 51 
Reactive airway disease 52 
Diseases of esophagus and peptic ulcer 53 
Malignant neoplasm 54 
Inflammatory polyarthritis and connective tissue disorders 55 
Pain 56 
Mycosis 57 
Bacterial infection or septicemia 58 
Thrombo-embolic risk or disease 59 
Hemorrhage risk or disease 60 
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t1 ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 12 0 2 
t2 ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 12 0 4 
t3 ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 11 0 2 
t4 ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕ 10 0 2 
t5 ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 9 0 4 
t6 ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 9 0 2 
t7 ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 9 2 3 
t8 ✓ ✕ ✕ ✕ ✕ ✕ ✕ 7 0 9 
t9 ✕ ✕ ✕ ✕ ✕ ✕ ✕ 7 0 2 
t10 ✓ ✓ ✕ ✕ ✕ ✕ ✕ 7 2 4 
t11 ✓ ✕ ✕ ✕ ✕ 5 0 29 
t12 ✓ ✕ ✕ ✕ 4 0 15 
t13 ✕ ✕ ✕ ✓ ✕ ✕ 6 0 7 
t14 ✕ ✓ ✕ ✓ ✕ ✕ 6 2 10 
t15 ✓ ✕ ✓ ✕ ✕ 5 2 8 
t16 ✓ ✓ ✕ ✕ 4 2 38 
t17 ✕ ✕ ✕ ✕ ✓ ✕ 6 0 6 
t18 ✕ ✕ ✕ ✓ ✓ ✕ 6 2 10 
t19 ✓ ✕ ✕ ✓ ✕ 5 2 9 
t20 ✓ ✕ ✕ ✓ ✕ 5 2 8 
t21 ✕ ✓ ✕ ✓ ✓ ✕ 6 3 14 
t22 ✓ ✓ ✕ ✓ ✓ ✕ 6 4 25 
t23 ✕ ✓ ✓ ✕ 4 2 40 
t24 ✓ ✓ ✓ ✕ 4 3 72 
t25 ✕ ✓ 2 0 22 
t26 ✕ ✕ ✕ ✓ ✓ 5 2 22 
t27 ✓ ✕ ✕ ✓ ✓ 5 3 38 
t28 ✕ ✕ ✕ ✓ ✓ ✓ 6 3 33 
t29 ✕ ✓ ✕ ✓ ✓ ✓ 6 4 47 
t30 ✕ ✓ ✕ ✓ ✓ ✓ 6 4 47 
t31 ✓ ✓ ✕ ✓ ✓ ✓ 6 5 64 
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p1 ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ 8 0 2 
p2 ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ 8 0 1 
p3 ✓ ✕ ✕ ✕ ✕ ✕ ✕ 7 0 2 
p4 ✕ ✓ ✕ ✕ ✕ ✕ 6 0 3 
p5 ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ 8 0 1 
p6 ✕ ✓ ✓ ✕ ✕ ✕ ✕ ✕ 8 2 4 
p7 ✓ ✓ ✕ ✕ ✕ ✕ ✕ 7 2 10 
p8 ✓ ✓ ✕ ✕ ✕ ✕ 6 2 4 
p9 ✓ ✕ ✕ ✕ 4 0 23 
p10 ✕ ✕ ✕ ✓ ✕ ✕ 6 0 4 
p11 ✓ ✕ ✕ ✓ ✕ ✕ 6 2 7 
p12 ✓ ✕ ✓ ✕ ✕ 5 2 6 
p13 ✕ ✕ ✓ ✓ ✕ ✕ 6 2 5 
p14 ✓ ✕ ✓ ✓ ✕ ✕ 6 3 13 
p15 ✓ ✓ ✓ ✕ ✕ 5 3 14 
p16 ✓ ✕ ✕ ✓ ✓ ✕ 6 3 12 
p17 ✕ ✓ ✕ ✕ ✓ ✕ 6 2 4 
p18 ✕ ✕ ✓ ✕ ✓ ✕ 6 2 6 
p19 ✕ ✓ ✓ ✕ ✓ ✕ 6 3 10 
p20 ✕ ✓ ✕ ✕ ✓ ✕ 6 2 4 
p21 ✓ ✓ ✕ ✕ ✓ ✕ 6 3 15 
p22 ✓ ✓ ✕ ✓ ✕ 5 3 13 
p23 ✕ ✕ ✕ ✕ ✓ ✓ ✕ 7 2 4 
p24 ✕ ✕ ✓ ✕ ✓ ✓ ✕ 7 3 7 
p25 ✓ ✕ ✕ ✓ ✓ ✕ 6 3 12 
p26 ✕ ✓ ✕ ✕ ✓ ✓ ✕ 7 3 6 
p27 ✕ ✓ ✓ ✕ ✓ ✓ ✕ 7 4 15 
p28 ✓ ✓ ✕ ✓ ✓ ✕ 6 4 25 
p29 ✕ ✕ ✓ ✓ ✓ ✕ 6 3 11 
p30 ✕ ✓ ✓ ✓ ✓ ✕ 6 4 19 
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p32 ✕ ✓ ✓ ✕ ✓ ✓ ✓ ✕ 8 5 23 
p33 ✕ ✓ ✓ ✓ ✓ ✓ ✕ 7 5 31 
p34 ✓ ✓ ✓ ✓ ✓ ✕ 6 5 44 
p35 ✕ ✕ ✕ ✕ ✓ 5 0 5 
p36 ✕ ✕ ✕ ✓ ✓ 5 2 9 
p37 ✓ ✕ ✕ ✓ 4 2 11 
p38 ✕ ✓ ✕ ✕ ✓ 5 2 10 
p39 ✕ ✓ ✓ ✕ ✓ 5 3 27 
p40 ✓ ✓ ✕ ✓ 4 3 34 
p41 ✕ ✓ ✕ ✕ ✓ 5 2 9 
p42 ✕ ✓ ✕ ✓ ✓ 5 3 18 
p43 ✕ ✕ ✓ ✓ 4 2 19 
p44 ✕ ✕ ✓ ✕ ✓ ✓ 6 3 24 
p45 ✕ ✓ ✓ ✕ ✓ ✓ 6 4 41 
p46 ✕ ✓ ✓ ✓ ✓ 5 4 51 
p47 ✓ ✓ ✕ ✓ ✓ 5 4 54 
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m1 ✕ ✕ ✕ ✕ ✕ ✕ 6 0 2 
m2 ✓ ✕ ✕ ✕ ✕ ✕ 6 0 4 
m3 ✓ ✕ ✕ ✕ ✕ 5 0 6 
m4 ✕ ✕ ✕ ✓ ✕ ✕ 6 0 6 
m5 ✕ ✓ ✕ ✓ ✕ ✕ 6 2 9 
m6 ✓ ✕ ✓ ✕ ✕ 5 2 24 
m7 ✓ ✕ ✕ 3 0 27 
m8 ✕ ✓ 2 0 18 
m9 ✕ ✕ ✕ ✕ ✕ ✓ ✕ 7 0 5 
m10 ✓ ✕ ✕ ✕ ✕ ✓ ✕ 7 2 7 
m11 ✕ ✓ ✕ ✕ ✓ ✕ 6 2 10 
m12 ✓ ✕ ✕ ✓ ✕ 5 2 27 
m13 ✓ ✕ ✓ ✕ 4 2 38 
m14 ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ 8 2 7 
m15 ✓ ✕ ✕ ✕ ✕ ✓ ✓ ✕ 8 3 14 
m16 ✓ ✕ ✕ ✕ ✓ ✓ ✕ 7 3 13 
m17 ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✓ ✕ 9 3 12 
m18 ✓ ✕ ✕ ✓ ✕ ✕ ✓ ✓ ✕ 9 4 17 
m19 ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ 8 4 20 
m20 ✕ ✓ ✓ ✕ ✓ ✓ ✕ 7 4 22 
m21 ✓ ✕ ✓ ✓ ✕ 5 3 34 
m22 ✕ ✓ ✓ ✓ ✕ 5 3 38 
m23 ✓ ✓ ✓ ✓ ✕ 5 4 56 
m24 ✕ ✕ ✓ ✓ 4 2 24 
m25 ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ 10 3 26 
m26 ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✓ ✓ 10 4 28 
m27 ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✓ ✓ 9 4 30 
m28 ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ 8 4 36 
m29 ✓ ✕ ✕ ✕ ✓ ✓ ✓ 7 4 36 
m30 ✕ ✓ ✕ ✓ ✓ ✓ 6 4 40 
m31 ✓ ✕ ✓ ✓ ✓ 5 4 47 
m32 ✓ ✓ ✓ 3 3 61 
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h1 ✕ ✕ ✕ ✕ 4 0 3 
h2 ✕ ✓ ✕ ✕ 4 0 5 
h3 ✓ ✕ ✕ 3 0 11 
h4 ✕ ✕ ✕ ✓ ✕ 5 0 5 
h5 ✕ ✕ ✕ ✓ ✓ ✕ 6 2 6 
h6 ✕ ✓ ✕ ✓ ✓ ✕ 6 3 10 
h7 ✓ ✕ ✓ ✕ 4 2 19 
h8 ✕ ✓ ✓ ✕ 4 2 12 
h9 ✓ ✓ ✓ ✕ 4 3 30 
h10 ✕ ✕ ✕ ✕ ✕ ✓ 6 0 16 
h11 ✕ ✕ ✕ ✕ ✓ ✓ 6 2 25 
h12 ✕ ✓ ✕ ✕ ✕ ✓ 6 2 10 
h13 ✕ ✓ ✕ ✕ ✕ ✓ ✓ 7 3 11 
h14 ✕ ✓ ✕ ✕ ✓ ✓ ✓ 7 4 19 
h15 ✕ ✓ ✕ ✓ 4 2 19 
h16 ✕ ✓ ✓ 3 2 27 
h17 ✓ ✕ ✓ 3 2 27 
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Table 7A – Cost estimates related to interaction and selected variables – Total healthcare 
  Percentile 
Variables 10 50 90 95 98
Diabetes (3) 562.37 853.85  62.20  -654.56 -1,962.34 
Heart failure (13) 208.51 719.12  6,603.54   12,456.31 17,254.25 
Hyperlipidemia (29) 632.50 861.43  484.84   100.49 -854.11 
Functional disorders of the digestive system (43) 348.01 1,085.54  4,195.11   5,747.84 8,846.50 
Ischemic heart diseases (51) 759.19 2,396.87 10,228.24   15,038.92 27,001.85 
Diseases of esophagus and peptic ulcer (53) 404.17 837.62  1,743.67   1,910.36 2,727.98 
Malignant neoplasm (54) 1,436.38 4,991.58 22,055.52   27,967.61 36,688.99 
Pain (56) 260.74 775.13  4,329.79   6,013.32 8,816.16 
Bacterial infection or septicemia (58) 155.01 513.56  2,465.25   4,480.23 7,640.62 
Thrombo-embolic risk or disease (59) 570.93 1,409.51 10,241.91   17,620.02 26,054.80 
t7 (3=1, 29=1, 36=0, 53=0, 54=0, 55=0, 56=0, 58=0, 59=0) 69.08 320.81  1,651.94   2,424.64 3,738.82 
t10 (29=1, 53=1, 54=0, 55=0, 56=0, 58=0, 59=0) -46.97 -3.30  223.54   465.41 227.01 
t14 (29=0, 53=1, 54=0, 56=1, 58=0, 59=0) -44.06 -45.46 -265.58   1,050.37 2,621.50 
t15 (29=1, 54=0, 56=1, 58=0, 59=0) -7.48 -147.71 -1,125.67  -769.09 675.78 
t16 (54=1, 56=1, 58=0, 59=0) -49.43 -899.92 -6,968.19  -10,807.11 -13,218.64 
t18 (29=0, 53=0, 54=0, 56=1, 58=1, 59=0) -65.84 -203.92 -1,397.72  -1,765.62 -2,769.69 
t19 (29=1, 53=0, 54=0, 58=1, 59=0) 41.96 -17.43 -303.95  -619.50 -1,177.83 
t20 (53=1, 54=0, 56=0, 58=1, 59=0) 11.13 -114.33 -694.03  -1,726.45 -3,123.01 
t23 (43=0, 54=1, 58=1, 59=0) 692.91 748.92 -1,043.69  -1,513.76 -4,800.69 
t26 (51=0, 54=0, 56=0, 58=1, 59=1) 193.74 286.87  1,965.04   2,428.46 4,275.61 
t21 (43=0, 53=1, 54=0, 56=1, 58=1, 59=0) 171.18 7.51 -1,389.79  -443.34 -2,352.72 
t22 (43=1, 53=1, 54=0, 56=1, 58=1, 59=0) 239.94 278.31  1,580.04   1,581.17 -810.74 
t24 (43=1, 54=1, 58=1, 59=0) 2,871.10 10,473.58 10,767.15   10,160.47 4,320.23 
t27 (51=1, 54=0, 56=0, 58=1, 59=1) 504.50 479.66  3,347.40  -26.80 -10,183.73 
t28 (43=0, 51=0, 54=0, 56=1, 58=1, 59=1) 449.69 1,417.24 11,532.32   10,105.81 6,937.52 
t29 (43=0, 51=1, 54=0, 56=1, 58=1, 59=1) 620.74 2,165.82 10,386.42   3,574.40 -15,141.26 
t30 (13=0, 43=1, 54=0, 56=1, 58=1, 59=1) 799.17 2,832.62 17,538.35   12,874.71 9,864.00 
t31 (13=1, 43=1, 54=0, 56=1, 58=1, 59=1) 1,679.52 6,989.78 18,743.12   17,563.37 5,712.70 
t32 (54=1, 58=1, 59=1) 2,438.98 9,313.10  9,151.72   1,279.73 -8,634.62 
Death in 2010 116.93 11,625.07 31,878.01   41,305.39 56,024.46 
Death in 2011 246.49 3,653.90 20,486.50   25,279.99 29,953.11 
Intercept 13.06 430.50  4,127.58   8,481.36 16,487.08 
Adj. R-square 0.1543 0.2383 0.3789 0.4199 0.4407
N 240,329 
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Table 8A – Cost estimates related to interaction and selected variables – Pharmaceutical  
Variables 
Percentile 
10 50 90 95 98
Diabetes mellitus (3) 255.68 560.17 1,109.86   1,362.10 1,528.46 
Mood [affective] disorders (6) 163.57 316.87  416.93   446.67 438.43 
Hypertensive disease (11) 125.87 200.46  287.59   330.05 551.31 
Hyperlipidemia (29) 294.35 610.43  776.77   839.59 821.19 
Reactive airway disease (52) 156.07 239.12  418.51   477.90 467.76 
Diseases of esophagus & peptic ulcer (53) 148.84 216.44  235.85   218.50 164.23 
Inflam. polyarthritis & connective tissue disord. (55) 77.68 182.55  834.64   1,314.46 4,367.85 
Pain (56) 83.86 98.06  145.56   124.19 66.47 
Bacterial infection or septicemia (58) 54.11 46.55  20.35   2.37 -37.49 
Thrombo-embolic risk or disease (59) 120.52 223.81  464.41   433.03 540.97 
p6 (3=0, 6=1, 29=1, 53=0, 54=0, 56=0,58=0, 59=0) 36.32 13.01  47.32   99.17 57.18 
p7 (3=1, 29=1, 53=0, 54=0, 56=0, 58=0, 59=0) 192.69 121.08  180.52   102.00 250.16 
p8 (29=1, 53=1, 54=0, 56=0, 58=0, 59=0) 62.49 72.11  141.34   159.57 211.67 
p11 (6=1, 29=0, 53=0, 56=1, 58=0, 59=0) -73.99 -93.75 -3.82   86.17 467.13 
p12 (29=1, 53=0, 56=1, 58=0, 59=0) 74.48 56.75  72.58   103.35 282.35 
p13 (6=0, 29=0, 53=1, 56=1, 58=0, 59=0) -51.99 52.55  134.53   282.27 541.17 
p17 (29=0, 52=1, 53=0, 56=0, 58=1, 59=0) -75.82 -27.01  104.68   179.90 240.89 
p18 (29=0, 52=0, 53=1, 56=0, 58=1, 59=0) -44.57 3.14  95.87   138.41 185.18 
p20 (3=0, 29=1, 53=0, 56=0, 58=1, 59=0) 61.72 37.91  110.65   114.22 141.49 
p23 (6=0, 29=0, 52=0, 53=0, 56=1, 58=1, 59=0) -55.22 -61.55 -25.21   32.61 98.77 
p36 (11=0, 29=0, 53=0, 56=1, 59=1) -55.30 -42.35 -102.77   142.10 460.56 
p37 (11=1, 29=0, 53=0, 59=1) -53.87 -77.33 -172.20  -146.21 -259.76 
p38 (3=0, 29=1, 52=0, 53=0, 59=1) 181.90 260.18  392.47   521.97 562.94 
p41 (29=0, 53=1, 55=0, 56=0, 59=1) -26.31 63.66  168.06   311.82 652.39 
p43 (29=0, 53=0, 55=1, 59=1) -35.11 -21.28  64.17   621.93 1,608.63 
p14 (6=1, 29=0, 53=1, 56=1, 58=0, 59=0) -28.15 67.18  206.70   309.22 911.01 
p15 (29=0, 53=1, 56=1, 58=0, 59=0) 195.19 171.29  302.74   427.53 668.31 
p16 (6=1, 29=0, 53=0, 56=1, 58=0, 59=0) -118.16 -106.41  83.13   471.72 753.33 
p19 (29=0, 52=1, 53=1, 56=1, 58=0, 59=0) 0.18 141.52  397.86   540.36 602.62 
p21 (3=1, 29=1, 53=0, 56=0, 58=1, 59=0) 134.91 35.07  153.57   143.60 365.51 
p22 (29=1, 53=1, 56=0, 58=1, 59=0) 189.14 181.83  265.64   288.46 520.73 
p24 (6=0, 29=0, 52=1, 53=0, 56=1, 58=1, 59=0) -107.53 0.45  263.10   385.02 456.88 
p26 (3=0, 29=1, 52=0, 53=0, 56=1, 58=1, 59=0) 75.06 40.81  61.80   95.81 256.38 
p27 (3=0, 29=1, 52=1, 53=0, 56=1, 58=1, 59=0) 109.08 107.84  252.33   307.13 298.04 
p28 (3=1, 29=1, 53=0, 56=1, 58=1, 59=0) 144.16 86.32  243.62   241.78 373.85 
p29 (29=0, 52=0, 53=1, 56=1, 58=1, 59=0) -54.05 73.22  242.31   348.62 689.25 
p30 (29=0, 52=1, 53=1, 56=1, 58=1, 59=0) 42.76 299.83  578.45   693.07 848.35 
p31 (3=0, 6=0, 29=1, 52=0, 53=1, 56=1, 58=1, 59=0) 216.60 214.28  358.81   430.88 683.48 
p32 (3=0, 6=1, 29=1, 52=0, 53=1, 56=1, 58=1, 59=0) 256.16 273.07  459.29   708.67 1,102.47 
p33 (3=0, 29=1, 52=1, 53=1, 56=1, 58=1, 59=0) 358.73 414.83  664.34   778.53 895.54 
p39 (3=0, 29=1, 52=1, 53=0, 59=1) 287.65 401.17  432.33   475.36 424.97 
p40 (3=1, 29=1, 53=0, 59=1) 289.86 292.61  322.22   286.65 274.05 
p42 (29=0, 53=1, 55=0, 56=1, 59=1) 79.12 184.45  300.66   522.19 861.33 
p44 (3=0, 6=0, 29=1, 52=0, 53=1, 59=1) 338.84 472.83  693.26   813.56 948.87 
p45 (3=0, 6=1, 29=1, 52=0, 53=1, 59=1) 475.51 508.35  588.78   850.23 1,000.73 
p46 (3=0, 29=1, 52=1, 53=1, 59=1) 545.13 800.61  880.58   993.75 930.12 
p47 (3=1, 29=1, 52=0, 53=1, 59=1) 600.08 641.27  627.23   623.61 546.16 
p48 (3=1, 29=1, 52=1, 53=1, 59=1) 784.58 957.76  741.37   607.39 372.06 
Death in 2010 -517.00 -653.80 -615.62  -696.17 -785.47 
Death in 2011 -1.01 169.78  905.94   1,531.13 3,675.42 
Intercept -105.06 17.96  451.53   670.50 1,136.69 
Adj. R-square 0.2125 0.3203 0.3451 0.3768 0.4328
N 162,741 
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Table 9A – Cost estimates related to interaction and selected variables – Medical services  
  Percentile 
Variables 10 50 90 95 98
Diabetes mellitus (3) 139.04 250.01  275.34   332.86 418.80 
Other mental and behavioral disorders (7) 71.34 123.20  162.05   185.63 295.09 
Conduction disord. & cardiac arrhythmias (12) 224.32 380.82  730.88   1,144.98 2,065.22 
Hyperlipidemia (29) 79.24 128.37  123.13   162.96 76.37 
Eye inflammation (36) 276.90 1,122.29  1,862.10   1,866.92 2,156.54 
Functional disorders of the digestive system (43) 154.62 354.61  641.50   847.16 796.91 
Ischemic heart diseases (51) 171.86 524.40  1,185.68   1,761.63 3,981.40 
Diseases of esophagus and peptic ulcer (53) 96.01 336.59  673.52   817.39 897.79 
Malignant neoplasm (54) 412.62 1,558.08  5,886.63   8,088.99 9,941.93 
Inflam. polyarthritis & connective tissue disord. (55) 165.09 375.99  584.25   675.04 809.69 
Pain (56) 84.30 262.67  862.55   1,095.39 1,407.79 
Bacterial infection or septicemia (58) 88.52 269.58  814.55   1,167.35 1,815.90 
Thrombo-embolic risk or disease (59) 118.06 486.87  2,065.08   2,793.45 3,323.25 
m5 (36=0, 53=1, 54=0, 56=1, 58=0, 59=0)  -25.24 -62.48  15.80  -65.19 -32.44 
m6 (36=1, 54=0, 56=1, 58=0, 59=0) -4.06 24.55 -51.85  -257.81 -479.20 
m10 (29=1, 36=0, 53=0, 54=0, 56=0, 58=1, 59=0) 2.98 14.13  118.32   23.91 138.21 
m11 (36=0, 53=1, 54=0, 56=0, 58=1, 59=0) 14.40 -48.45 -120.02  -331.69 -393.25 
m12 (36=1, 54=0, 56=0, 58=1, 59=0) 23.52 39.15  490.87   194.25 -478.88 
m13 (54=1, 56=0, 58=1, 59=0) 233.61 297.20  1,585.35   1,400.19 2,537.31 
m14 (7=0, 29=0, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) -15.65 -6.65 -191.79  -364.86 -995.69 
m24 (54=0, 56=0, 58=1, 59=1) 121.28 225.92  273.11   297.08 721.75 
m15 (7=1, 29=0, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) 52.82 117.57  425.14   466.82 53.13 
m16 (29=1, 36=0, 53=0, 54=0, 56=1, 58=1, 59=0) 22.01 121.72  250.60   28.46 -492.11 
m17 (3=0, 36=0, 43=0, 53=1, 54=0, 55=0, 56=1, 58=1, 59=0) 36.47 5.18 -261.00  -367.13 -713.92 
m18 (3=1, 36=0, 43=0, 53=1, 54=0, 55=0, 56=1, 58=1, 59=0) 211.81 315.44  67.73   57.44 -758.93 
m19 (36=0, 43=0, 53=1, 54=0, 55=1, 56=1, 58=1, 59=0) 55.44 112.97 -29.39  -381.41 -1,128.68 
m20 (36=0, 43=1, 53=1, 54=0, 56=1, 58=1, 59=0) 100.49 153.57  402.72   145.25 174.27 
m21 (36=1, 54=0, 56=1, 58=1, 59=0) 98.37 103.25  53.26  -51.59 -686.96 
m22 (43=0, 54=1, 56=1, 58=1, 59=0) 171.27 -49.80 -1,736.06  -2,188.90 -2,332.21 
m23 (43=1, 54=1, 56=1, 58=1, 59=0) 433.46 1,064.92  63.76  -811.74 -2,448.91 
m25 (12=0, 36=0, 43=0, 51=0, 53=0, 54=0, 55=0, 56=1, 58=1, 59=1) 186.82 422.21  1,346.45   1,174.50 537.81 
m26 (12=0, 36=0, 43=0, 51=0, 53=1, 54=0, 55=0, 56=1, 58=1, 59=1) 190.03 339.84  741.76   406.23 546.32 
m27 (12=0, 36=0, 43=0, 51=1, 54=0, 55=0, 56=1, 58=1, 59=1) 229.76 230.16  161.12   1,216.46 86.07 
m28 (12=0, 36=0, 43=0, 54=0, 55=1, 56=1, 58=1, 59=1) 268.53 460.43  1,044.81   971.39 3,022.20 
m29 (12=1, 36=0, 43=0, 54=0, 56=1, 58=1, 59=1) 380.14 635.50  1,420.89   4,433.85 5,700.94 
m30 (36=0, 43=1, 54=0, 56=1, 58=1, 59=1) 274.43 542.38  2,186.65   2,873.15 4,639.93 
m31 (36=1, 54=0, 56=1, 58=1, 59=1) 460.10 247.55  440.70  -142.09 681.28 
m32 (54=1, 58=1, 59=1) 695.61 1,422.68  2,676.18   2,045.60 2,295.15 
Death in 2010 -435.21 -621.83 -487.91  -232.34 1,083.99 
Death in 2011 -43.09 152.96  1,003.94   2,137.52 2,865.12 
Intercept 130.33 564.74  2,048.40   2,910.30 4,567.92 
Adj. R-square 0.0963 0.1837 0.2798 0.3106 0.3470
N 228,545 












Multimorbidities and health care expenditure 
 
 
Table 10A – Cost estimates related to interaction and selected variables – Hospital  
  Percentile 
Variables 10 50 90 95 98 
Heart failure (13) 95.29 1,643.50  9,694.00   16,413.27 31,702.40 
Hyperlipidemia (29) -2.42 -213.99 -999.29  -1,367.05 -1,838.15 
Functional disorders of the digestive system (43) 7.76 269.05  3,684.00   4,942.76 5,412.43 
Ischemic heart diseases (51) 294.85 2,020.43  9,868.19   14,863.01 15,968.90 
Malignant neoplasm (54) 288.74 1,459.20  7,999.12   7,841.32 7,361.97 
Pain (56) 124.56 765.45  3,383.00   4,365.71 4,004.67 
Bacterial infection or septicemia (58) 58.74 795.36  3,617.08   4,434.56 5,278.71 
Thrombo-embolic risk or disease (59) 224.58 4,091.19 21,015.05   23,517.84 29,890.76 
h5 (13=0, 43=0, 54=0, 56=1, 58=1, 59=0) -41.73 -257.21 -222.60  -98.72 2,204.26 
h7 (13=1, 54=0, 58=1, 59=0) 4.08 -57.18  3,881.69   2,242.88 -14,027.48 
h8 (43=0, 54=1, 58=1, 59=0) -9.76 -2.13 -708.88   1,167.39 2,147.30 
h11 (13=0, 29=0, 51=0, 54=0, 56=1, 59=1) 2.12 2,391.47  2,626.44   5,172.50 6,690.70 
h12 (13=0, 29=1, 51=0, 54=0, 58=0, 59=1) -146.10 -2,784.36 -9,469.17  -8,834.80 -10,951.02 
h15 (13=0, 51=1, 54=0, 59=1) -7.48 947.35 -8,680.26  -14,056.61 -16,172.65 
h16 (13=0, 54=1, 59=1) 390.49 1,946.58 -6,638.91  -8,786.40 -14,814.12 
h17 (13=1, 43=0, 59=1) 19.11 -1,300.46 -7,442.80  -10,434.58 -21,157.14 
h6 (13=0, 43=1, 54=0, 56=1, 58=1, 59=0) -55.04 224.63  289.33   633.82 7,601.27 
h9 (43=1, 54=1, 58=1, 59=0) 428.82 4,325.21  5,785.55   8,268.86 14,851.54 
h13 (13=0, 29=1, 51=0, 54=0, 56=0, 58=1, 59=1) -77.31 -2,340.71 -8,935.27  -3,732.51 -2,860.28 
h14 (13=0, 29=1, 51=0, 54=0, 56=1, 58=1, 59=1) -61.10 -664.52 -3,498.04  -3,637.96 -4,415.81 
h18 (13=1, 43=1, 59=1) 733.10 5,103.90  873.53  -4,252.38 -15,007.17 
Death in 2010 2,710.33 13,081.06 29,974.96   36,836.50 50,140.64 
Death in 2011 625.45 6,687.20 19,441.13   23,185.52 27,840.16 
Intercept 1,288.27 3,034.48 15,246.14   24,893.88 40,660.58 
Adj. R-square 0.0224 0.1048 0.2468 0.2646 0.2810
N 64,432 
Note: the relevant morbidity IDs are shown in brackets and correspond with those shown in Table 2°. 
 
